BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) have been given an average rating of “Moderate Buy” by the five brokerages that are currently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $15.60.

A number of equities research analysts recently weighed in on BCRX shares. Royal Bank of Canada reissued an “outperform” rating and issued a $10.00 price target on shares of BioCryst Pharmaceuticals in a research report on Tuesday, November 5th. Barclays boosted their target price on BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the company an “equal weight” rating in a report on Tuesday, November 5th. Finally, Needham & Company LLC restated a “buy” rating and set a $14.00 price target on shares of BioCryst Pharmaceuticals in a research note on Tuesday, November 5th.

BioCryst Pharmaceuticals Stock Performance

Shares of NASDAQ BCRX opened at $7.71 on Friday. The stock’s 50-day simple moving average is $7.64 and its 200-day simple moving average is $7.46. The firm has a market capitalization of $1.60 billion, a PE ratio of -12.64 and a beta of 1.79. BioCryst Pharmaceuticals has a fifty-two week low of $4.03 and a fifty-two week high of $8.88.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its quarterly earnings data on Monday, November 4th. The biotechnology company reported ($0.07) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.07). The company had revenue of $117.10 million for the quarter, compared to analyst estimates of $113.99 million. During the same period in the previous year, the business posted ($0.19) EPS. The firm’s revenue for the quarter was up 35.1% compared to the same quarter last year. On average, sell-side analysts forecast that BioCryst Pharmaceuticals will post -0.38 earnings per share for the current fiscal year.

Institutional Investors Weigh In On BioCryst Pharmaceuticals

Hedge funds have recently modified their holdings of the stock. Principal Financial Group Inc. raised its holdings in BioCryst Pharmaceuticals by 1,058.1% during the third quarter. Principal Financial Group Inc. now owns 411,414 shares of the biotechnology company’s stock worth $3,127,000 after purchasing an additional 375,890 shares in the last quarter. Exome Asset Management LLC purchased a new position in shares of BioCryst Pharmaceuticals during the 3rd quarter worth approximately $1,493,000. Franklin Resources Inc. lifted its holdings in shares of BioCryst Pharmaceuticals by 177.8% in the 3rd quarter. Franklin Resources Inc. now owns 263,748 shares of the biotechnology company’s stock valued at $1,968,000 after buying an additional 168,790 shares during the period. Sanctuary Advisors LLC boosted its stake in shares of BioCryst Pharmaceuticals by 78.3% in the third quarter. Sanctuary Advisors LLC now owns 47,389 shares of the biotechnology company’s stock valued at $360,000 after buying an additional 20,818 shares in the last quarter. Finally, SkyView Investment Advisors LLC grew its holdings in BioCryst Pharmaceuticals by 30.0% during the third quarter. SkyView Investment Advisors LLC now owns 13,000 shares of the biotechnology company’s stock worth $99,000 after acquiring an additional 3,000 shares during the period. 85.88% of the stock is owned by institutional investors and hedge funds.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.